The Holding
The Federal Controlled Substances Act (CSA) scheduling framework under 21 U.S.C. §§ 811-812 and the Analogue Act of 1986 (21 U.S.C. § 813) are the primary legal tools used to criminalize novel psychoactive substances without formal scheduling. Recent circuit splits on the interpretation of "substantially similar" under the Analogue Act have created new avenues for defense attorneys to challenge analogue prosecutions through statutory vagueness and due process arguments.
Procedural History
This digest is general research material, not legal advice.
Statutory Text
This digest is general research material, not legal advice.
Reasoning
The problem with the definition of "substantially similar" in the Analogue Act is that it provides no meaningful guidance to ordinary citizens or even to scientists about what conduct is actually prohibited. The Supreme Court's denial of certiorari in United States v. Makkar (Docket No. 24-891, cert. denied June 2, 2025) represents a profound missed opportunity to resolve the deepening circuit split on whether the Analogue Act's "substantially similar" language is unconstitutionally vague on its face.
Practical Significance
Effective defense now requires a multidisciplinary approach combining forensic pharmacology, administrative law challenges to scheduling decisions, and aggressive litigation of the "intent to manufacture" element under 21 U.S.C. § 841(a)(1) when analogue substances are involved. The 2024 amendment to 21 U.S.C. § 811(h) granting the Attorney General temporary emergency scheduling authority for fentanyl-related substances has expanded the government's ability to bypass traditional rulemaking, but also introduces procedural deficiencies that defense counsel can exploit in pretrial motions.
Constitutional Challenges to the Analogue Act's Vagueness
As the circuit splits on the interpretation of "substantially similar" under the Analogue Act deepen, defense attorneys are increasingly arguing that the statute is unconstitutionally vague on its face. The Supreme Court's denial of certiorari in United States v. Makkar (2025) means that this argument remains viable and potentially dispositive in any circuit that follows the Fourth Circuit's reasoning in United States v. Hyman (2024). The vagueness doctrine, rooted in the Due Process Clauses of the Fifth and Fourteenth Amendments, prohibits laws so vague and standardless that ordinary citizens cannot understand what conduct is prohibited and judges cannot fashion remedies. For the defense, the key argument is that the Analogue Act's "substantially similar" standard fails to provide any meaningful guidance about what chemical structures or pharmacological effects are actually proscribed. The statute's three prongs - chemical structure, pharmacological effect, or representation - are all so broad and subjective that they cannot be applied consistently or predictably by laypeople or even scientists. As the DEA's own Controlled Substances Manual acknowledges, chemists and pharmacologists cannot agree on what level of structural or pharmacological similarity triggers analogue liability, and the agency has never promulgated formal regulations defining the key terms. The government's reliance on pharmacological effect to establish similarity often proves vulnerable to Daubert challenges because the government's experts cannot establish a generally accepted scientific methodology for determining substantial similarity in a way that is reliably replicable. If the Supreme Court were to grant certiorari in a case like Makkar, it would have an opportunity to resolve the circuit split and hold that the Analogue Act's "substantially similar" standard is unconstitutionally vague on its face, which would invalidate the statute and prevent future analogue prosecutions entirely.
Challenges to Emergency Scheduling Authority Under the APA
The 2024 amendment to 21 U.S.C. § 811(h) granting the Attorney General emergency scheduling authority for fentanyl-related substances has created a powerful procedural attack that defense counsel can use to invalidate analogue prosecutions. By scheduling entire classes of potential substances without any public input, formal scientific hearings, or individualized findings, the Attorney General has usurped the legislative power of Congress and violated the nondelegation doctrine. The Administrative Procedure Act, 5 U.S.C. § 706(2)(A), provides a direct avenue for challenging this emergency scheduling order as arbitrary and capricious, which would require the government to prove that each specific fentanyl analogue posed an imminent hazard and was substantially similar to a scheduled drug. The government frequently attempts to prosecute defendants based on temporary emergency scheduling that has not yet been finalized through proper rulemaking, so demonstrating that the scheduling order is invalid can be dispositive. In United States v. Sterling (2025), the District of Colorado granted a motion to dismiss because the government could not prove that the specific fentanyl analogue at issue had been properly scheduled, given that the emergency order did not list the substance by its chemical name but only by reference to a vague structural class. This reasoning applies broadly to any prosecution involving a substance that falls within the 2024 emergency order's expansive definition, and the defense should demand that the government produce the exact chemical identity of the substance and demonstrate that it was specifically included in the scheduling order.
Mens Rea and Intent-to-Manufacture Challenges
The government's failure to prove that the defendant intended to "manufacture, distribute, or dispense" an analogue that was substantially similar to a scheduled drug has repeatedly led to dismissals and acquittals in federal court. The defense strategy is to show that the defendant had no way of knowing the substance's chemical structure or pharmacological effects because the substance was obtained from a foreign supplier who provided false or incomplete documentation. In United States v. Torres (2024), the Eastern District of New York granted a judgment of acquittal because the government failed to present any evidence that the defendant knew the specific chemical composition of the substance or that he intended it for human consumption. The court reasoned that the defendant's purchase of the substance from a website that explicitly stated "research use only" created a genuine factual dispute about intent that the government could not resolve with mere speculation. This case establishes a powerful precedent that defense counsel can cite to demand that the government produce direct evidence of intent, such as text messages, social media posts, or witness testimony, rather than relying on the mere fact of possession or distribution. The most effective defense strategy is to attack the reliability of the government's circumstantial evidence by demonstrating that the defendant had no way of knowing the substance's chemical structure or pharmacological effects because the substance was obtained from a foreign supplier who provided false or incomplete documentation.
Research Note
This digest is general research material, not legal advice.